New combo aims to stop liver cancer return after surgery
NCT ID NCT04912765
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests a personalized vaccine made from a patient's own immune cells combined with an immunotherapy drug (nivolumab) to prevent liver cancer or colorectal cancer that has spread to the liver from coming back after surgery. About 60 participants will receive the vaccine and nivolumab after their tumor is removed. The goal is to see if this treatment improves cancer-free survival and boosts the immune system against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Singapore
RECRUITINGSingapore, 169690, Singapore
Conditions
Explore the condition pages connected to this study.